- Home
- BMGL vs OSTX Comparison
BMGL vs OSTX Comparison
Compare BMGL & OSTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMGL
- OSTX
- Stock Information
- Founded
- BMGL 2001
- OSTX 2018
- Country
- BMGL Singapore
- OSTX United States
- Employees
- BMGL N/A
- OSTX N/A
- Industry
- BMGL
- OSTX
- Sector
- BMGL
- OSTX
- Exchange
- BMGL NYSE
- OSTX NYSE
- Market Cap
- BMGL 36.1M
- OSTX 43.0M
- IPO Year
- BMGL 2025
- OSTX 2024
- Fundamental
- Price
- BMGL $2.02
- OSTX $1.75
- Analyst Decision
- BMGL
- OSTX Strong Buy
- Analyst Count
- BMGL 0
- OSTX 3
- Target Price
- BMGL N/A
- OSTX $18.00
- AVG Volume (30 Days)
- BMGL 6.7M
- OSTX 350.5K
- Earning Date
- BMGL 01-01-0001
- OSTX 08-14-2025
- Dividend Yield
- BMGL N/A
- OSTX N/A
- EPS Growth
- BMGL N/A
- OSTX N/A
- EPS
- BMGL 0.02
- OSTX N/A
- Revenue
- BMGL $7,342,469.00
- OSTX N/A
- Revenue This Year
- BMGL N/A
- OSTX N/A
- Revenue Next Year
- BMGL N/A
- OSTX N/A
- P/E Ratio
- BMGL $113.17
- OSTX N/A
- Revenue Growth
- BMGL 2.28
- OSTX N/A
- 52 Week Low
- BMGL $0.91
- OSTX $1.12
- 52 Week High
- BMGL $9.40
- OSTX $7.00
- Technical
- Relative Strength Index (RSI)
- BMGL N/A
- OSTX N/A
- Support Level
- BMGL N/A
- OSTX N/A
- Resistance Level
- BMGL N/A
- OSTX N/A
- Average True Range (ATR)
- BMGL 0.00
- OSTX 0.00
- MACD
- BMGL 0.00
- OSTX 0.00
- Stochastic Oscillator
- BMGL 0.00
- OSTX 0.00
About BMGL BASEL MEDICAL GROUP LTD
Basel Medical Group Ltd provides general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. Key revenue is generated from Singapore.
About OSTX OS THERAPIES INCORPORATED
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the need for new treatments in cancers of the bone in children and young adults.